Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the study is to demonstrate that siltuximab will delay progression of high-risk SMM as measured by the 1 year progression-free survival (PFS) rate.
Inclusion criteria
- High-risk Smoldering Multiple Myeloma